OSSTEC published 12-week preclinical results showing equivalent fixation for titanium and cobalt chromium alloy implants with cementless technology.
Public source
Publisher name
Public post
Biological fixation with OSSTEC's cementless technology strengthens over time. Our 12-week preclinical results show equivalent fixation for our titanium and cobalt chrom…
Company
OSSTEC
Simpler joint replacement surgery. Biomimetic printing technology.
- Industry
- Medical Equipment Manufacturing
- Location
- London, GB
- Company size
- 11–50 employees
About OSSTEC
OSSTEC is a medical technology company developing the next generation of cementless orthopaedic implants. Our lead product, ASCENT, is a cementless partial knee replacement designed to preserve healthy anatomy, restore natural movement and help patients remain active for longer. It combines advanced 3D-printed, bone-mimetic fixation with a simplified surgical workflow built for modern arthroplasty. Our technology is underpinned by more than a decade of research and developed through close collaboration between engineers, scientists and leading orthopaedic surgeons. We believe the future of partial knee replacement is cementless - and we are building the technology to make it simpler, more reproducible and more widely accessible.
See moreLatest activity
Latest activity from OSSTEC
5 signals
People
OSSTEC appointed Alex Liddle, MD PhD, as Chief Medical Officer and Consultant Orthopaedic Surgeon.
Products & Services
OSSTEC Chief Medical Officer Alex Liddle leads clinical strategy to ensure ASCENT and CLARITY are grounded in evidence and shaped by surgeons.
Presence & Recognition
OSSTEC is presenting its full results at ISTA Munich in September.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
GreenBone Ortho
GreenBone Ortho published a study in Biomaterials Science describing interconnected multiscale porosity, damage-tolerant mechanical behaviour, osteogenic gene expression in vitro, and osteoinductive bone formation in vivo.
Research & Knowledge
4WEB
4WEB Medical published research on Truss Implant Technology, which provides a synergistic relationship between hierarchical surface roughness and macro architecture.
Research & Knowledge
Biocomposites
Biocomposites reported a retrospective review of 17 patients with open fracture defects and non-unions treated with NanoBone® where all patients achieved union with an average time to union of 7.5 weeks.
Research & Knowledge
Anika
Anika Therapeutics published a 10-year follow-up study of 101 patients with osteochondral lesions of the talus showing that Hyalofast demonstrated durable clinical benefits with 85% satisfaction and 5% requiring further surgical intervention.
Research & Knowledge
Smith+Nephew